Translate Bio Expands Collaboration with Sanofi For Infectious Disease Vaccines
20 Julho 2020 - 06:54PM
Dow Jones News
By Kimberly Chin
Translate Bio Inc. has expanded its collaboration and licensing
agreement with Sanofi SA to develop vaccines for infectious
diseases, including Covid-19, using messenger RNA therapeutics.
Sanofi will give Translate Bio $425 million up front and common
stock equity in the deal. Translate Bio will also be able to get up
to $1.9 billion should it hit potential milestones, as well as
other payments and tiered royalties on worldwide sales of
successful vaccines. Sanofi will also pay all of the
collaboration's costs during the agreement term.
In exchange, Sanofi will have exclusive worldwide rights to all
of the vaccines developed, Translate Bio said.
Translate Bio and Sanofi Pasteur Inc., the global vaccines
business unit of Sanofi, partnered in 2018 under an exclusive
license agreement to develop mRNA vaccines for up to five
infectious diseases. The collaboration was expanded in March to
include a new mRNA vaccine for Covid-19, the disease caused by the
novel coronavirus.
Messenger RNA, or mRNA, is a piece of genetic code that carries
the instructions from a person's own DNA telling cells what to
do.
Moderna Inc., considered one of the front-runners in the race to
find a Covid-19 vaccine, also uses mRNA to develop its potential
candidate. Moderna aims to synthesize mRNA with instructions for
attacking a disease or pathogen, and then give it to patients.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
July 20, 2020 17:39 ET (21:39 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024